Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 360 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2023
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Vachliotis, I. D., Valsamidis I., & Polyzos S. A. (2023).  Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.. Cancers (Basel). 15(21), 
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
2022
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Tzitiridou-Chatzopoulou M., Chatzopoulos D., et al. (2022).  Adverse Outcomes of E-cigarette in Inflammatory Bowel Disease.. Dig Dis Sci.
Polyzos, S. A., Goulis D. G., Giouleme O., Germanidis G. S., & Goulas A. (2022).  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Vachliotis, I. D., Vasiloglou M. F., Kapama A., Matsagkos D., Goulas A., Papaioannidou P., et al. (2022).  Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life.. Arab J Gastroenterol.
Tontikidou, C., Makri E. S., Evripidou K., Goulis D. G., Goulas A., & Polyzos S. A. (2022).  Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Makri, E. S., Makri E., & Polyzos S. A. (2022).  Combination Therapies for Nonalcoholic Fatty Liver Disease.. J Pers Med. 12(7), 
Rupp, S., Papaefthymiou A., Chatzimichael E., Polyzos S. A., Spreitzer S., Doulberis M., et al. (2022).  Diagnostic approach to -related gastric oncogenesis.. Ann Gastroenterol. 35(4), 333-344.
Anastasilakis, A. D., Papachatzopoulos S., Makras P., Gkiomisi A., Nikolakopoulos P., Polyzos S. A., et al. (2022).  The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. Bone. 158, 116354.
Kountouras, J., Doulberis M., Polyzos S. A., Kazakos E., Vardaka E., Tzitiridou-Chatzopoulou M., et al. (2022).  Emerging parameters relevant to the management of antimicrobial-resistant Helicobacter pylori infection.. Intern Med J. 52(9), 1654-1655.
Kountouras, J., Kazakos E., Polyzos S. A., Chatzopoulos D., Tzitiridou-Chatzopoulou M., Doulberis M., et al. (2022).  GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.. Helicobacter. 27(3), e12884.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kazakos E., Vardaka E., Touloumtzi M., et al. (2022).  Impact of Active Helicobacter pylori Infection-related Metabolic Syndrome on Systemic Arterial Hypertension.. Arq Bras Cardiol. 119(3), 502-504.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Vardaka E., Touloumtzi M., et al. (2022).  Letter to the Editor Regarding "The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy" by Abeid et al.. Obes Surg. 32(6), 2079-2080.
Polyzos, S. A., Lambrinoudaki I., & Goulis D. G. (2022).  Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.. Hormones (Athens).
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Tzitiridou-Chatzopoulou M., Chatzopoulos D., et al. (2022).  Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease.. Metabolism. 135, 155276.
Kountouras, J., Papaefthymiou A., Polyzos S. A., & Doulberis M. (2022).  Potential Impact of Helicobacter pylori Infection on Pancreatic Cancer Pathophysiology.. J Gastrointest Cancer.
Kountouras, J., Doulberis M., Polyzos S. A., Tzitiridou M., Chatzopoulos D., Gialamprinou D., et al. (2022).  A potential impact of Helicobacter pylori-related metabolic syndrome on early and long-term outcomes of bariatric surgery.. Gastrointest Endosc. 96(6), 1088-1089.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές